The association of propofol with excitatory motor activity, such as myoclonic jerking and opisthotonus, in humans and in animals suggests that it may aggravate clinical seizure activity in some circumstances, although evidence suggests that under other circumstances, propofol inhibits seizure activity. In the current study, we assessed the effect of sedating doses of propofol on lidocaine-induced seizure activity in spontaneously breathing rats receiving no other anesthetics. Adult Sprague-Dawley male rats, 300-400 g, were divided into a control group and three experimental groups representing three graded levels of propofol sedation. The control rats then received a lidocaine infusion at the rate of 150 mg * kg-' . h-i, resulting in a slow, progressive increase in systemic lidocaine concentrations. At the onset of electroencephalographic (EEG) seizure activity, arterial lidocaine concentrations were obtained. The treated rats received propofol according to three different dose schedules: Dose 1 = 10 mg * kg-' * h-' after a 2.5-mg/kg bolus; Dose 2 = 20 mg * kg-r * h-' afte r a 5-mg/kg bolus; Dose 3 = 40 mg * kg-' * h-l after a lo-mg/kg bolus. After 30 min, a steady level of sedation, dependent on the dose of propofol, was achieved. The lidocaine infusion was then started, and systemic lidocaine levels were obtained at the onset of EEG seizure activity. The lidocaine was continued until the onset of death by cardiac arrest. Plasma lidocaine was measured by gas chromatography. Analysis of variance and Dunnett's t-test were used for comparisons with the control values. Continuous propofol sedation increased the seizure dose of lidocaine from 37.7 ? 3.5 mg/kg (mean 5 SEM) to 52.5 2 2.6 mg/kg (Dose 1, P < 0.05) and 67.9 2 8.6 mg/kg (Dose 2, P < 0.05), and completely abolished lidocaine seizures at Dose 3. The lethal dose of lidocaine, 89.4 ? 10.5 mg/kgcontrolversus 108.7 ? 10.3 mg/kg (Dose l), 98.3 5 10.1 mg/kg (Dose 2), and 93.5 ? 10.4 mg/kg (Dose 3) did not differ among groups. The lidocaine levels at seizure threshold were increased in the propofoltreated rats: 16.9 -C 0.5 pg/mL control versus 19.2 5 0.7 pg/mL (Dose 1, P = not significant) and 23.7 ?
The association of propofol with excitatory motor activity, such as myoclonic jerking and opisthotonus, in humans and in animals suggests that it may aggravate clinical seizure activity in some circumstances, although evidence suggests that under other circumstances, propofol inhibits seizure activity. In the current study, we assessed the effect of sedating doses of propofol on lidocaine-induced seizure activity in spontaneously breathing rats receiving no other anesthetics. Adult Sprague-Dawley male rats, 300-400 g, were divided into a control group and three experimental groups representing three graded levels of propofol sedation. The control rats then received a lidocaine infusion at the rate of 150 mg * kg-' . h-i, resulting in a slow, progressive increase in systemic lidocaine concentrations. At the onset of electroencephalographic (EEG) seizure activity, arterial lidocaine concentrations were obtained. The treated rats received propofol according to three different dose schedules: Dose 1 = 10 mg * kg-' * h-' after a 2.5-mg/kg bolus; Dose 2 = 20 mg * kg-r * h-' afte r a 5-mg/kg bolus; Dose 3 = 40 mg * kg-' * h-l after a lo-mg/kg bolus. After 30 min, a steady level of sedation, dependent on the dose of propofol, was achieved. The lidocaine infusion was then started, and systemic lidocaine levels were obtained at the onset of EEG seizure activity. The lidocaine was continued until the onset of death by cardiac arrest. Plasma lidocaine was measured by gas chromatography. Analysis of variance and Dunnett's t-test were used for comparisons with the control values. Continuous propofol sedation increased the seizure dose of lidocaine from 37.7 ? 3.5 mg/kg (mean 5 SEM) to 52.5 2 2.6 mg/kg (Dose 1, P < 0.05) and 67.9 2 8.6 mg/kg (Dose 2, P < 0.05), and completely abolished lidocaine seizures at Dose 3. The lethal dose of lidocaine, 89.4 ? 10.5 mg/kgcontrolversus 108.7 ? 10.3 mg/kg (Dose l), 98.3 5 10.1 mg/kg (Dose 2), and 93.5 ? 10.4 mg/kg (Dose 3) did not differ among groups. The lidocaine levels at seizure threshold were increased in the propofoltreated rats: 16.9 -C 0.5 pg/mL control versus 19.2 5 0.7 pg/mL (Dose 1, P = not significant) and 23.7 ? 1.8 pg/mL (Dose 2, P < 0.05). Continuous propofol sedation in spontaneously breathing rats receiving no other anesthetics exerts a protective effect against lidocaine-induced seizures in a monotonic, dosedependent fashion. The cardiac arrest dose of lidocaine is unaffected by propofol under these conditions. Implications:
The IV anesthetic drug propofol, given to rats to produce sedation, was found to suppress seizure activity caused by overdosage of the local anesthetic lidocaine.
(Anesth Analg 1998;86:652-7)
A fter initial reports that propofol is capable of producing excitatory motor activity, such as opisthotonus and aggravation of electroencephalographic seizure activity in known epileptic patients (l-4), concern has been expressed about the ability of propofol to provoke or to potentiate seizure activity. On the other hand, a number of animal studies have demonstrated an anticonvulsant effect of propofol using different models of experimentally induced epilepsy, including seizure induction by pentylenetetrazol as well as by transcranial electrical shock (5-8). Two studies have examined the issue of local anesthetic-induced seizures and the apparent anticonvulsant effects of propofol (9,lO). However, in both studies, the rats received inhaled volatile anesthetics by controlled lung ventilation in addition to the propofol. In the present study, we examined the effect of propofol sedation on lidocaine-induced seizures in spontaneously breathing rats receiving no other anesthetics. This particular experimental design is relevant to the situation of spontaneously breathing human patients under propofol sedation who are concomitantly receiving doses of local anesthetic drugs in conjunction with regional anesthesia and surgery.
Methods
In accordance with an institutionally approved animal research protocol, male Sprague-Dawley rats, 300-400 g, 652 Anesth Analg 1998; 86:652-7 were briefly anesthetized with inhaled isoflurane. The central tail artery and two lateral tail veins were percutaneously cannulated with 24-gauge intravascular catheters, a rectal temperature probe was placed, and three platinum needle recording electrodes were sutured into the scalp overlying the midline and overlying the right and left parietal cortices. A fourth electrode was sutured into the midline of the lumbodorsal region as described below. The rats recovered rapidly from the brief isoflurane anesthesia inside a circumferential restraining cage, which permitted limited movement but prevented the animal from turning or dislodging the vascular catheters and recording electrodes. After recovery, the rats were alert, spontaneously active, and breathing room air. Continuous monitoring of arterial blood pressure, rectal temperature, vital signs, and arterial blood gases was performed. External radiant heat was intermittently used to maintain thermal homeostasis, based on rectal temperatures. After a minimum of 30 min after termination of isoflurane anesthesia, at which time the rats were fully awake and quietly resting, the rats received drug infusions according to the following protocol. There were four groups (a control group and three experimental propofol groups) with n = 6 for each group. After recovery from isoflurane anesthesia and after baseline data had been obtained (vital signs and arterial blood gas determinations), the rats in the control group received a lidocaine infusion at the rate of 150 mg * kg-' * h-i without a bolus, resulting in a controllable and slowly increasing level of lidocaine in the systemic circulation, allowing more equilibration between systemic and brain levels of lidocaine than can be achieved with a rapidly increasing lidocaine level. This technique of inducing lidocaine seizures was similar to that previously reported (ll), and seizure onset and subsequent cardiac arrest occurred within a predictable time interval after initiation of the infusion. At the onset of seizure activity, the lidocaine dose was recorded, and the lidocaine plasma level was determined. Vital signs and arterial blood gas data were also determined at seizure onset to verify that hypoxemia, hypercarbia, hypotension, or other physiologic derangements were not contributory factors. The lidocaine infusion was continued until the time of cardiac arrest, and the lethal dose of lidocaine was recorded. The present methodology did not permit lidocaine level determination at the time of cardiac arrest.
Pilot studies established that three empirically determined propofol dosage schedules were capable of inducing graded and distinguishable levels of sedation (Table l) , as determined by observations of behavioral and reflex activity in rats. The maximal propofol dosage schedule, although sedating, was subanesthetic because it did not abolish the tail forceps pinch response. Each of these dosage schedules was initiated after a minimum of 30 min recovery from isoflurane anesthesia and after baseline data collection. For Dose 1, a propofol bolus of 2.5 mg/kg was given, followed by an infusion of 10 mg * kg-* * h-l. For Dose 2, a propofol bolus of 5 mg/kg was p, followed by an infusion of 20 mg * kg-i * h-. For Dose 3, a propofol bolus of 10 mg/kg was given, followed by an infusion of 40 mg * kg-' * h-l. The rats achieved a stable level of sedation for a period of 30 min after each of the propofol dose regimens. After collection of vital sign and arterial blood gas data, the rats were infused with lidocaine and determinations of seizure threshold and lethal dosages were made as described above. The drug solutions were prepared fresh daily from the following stock: preservative-free lidocaine HCl solution 10 mg/ mL, and propofol emulsion 10 mg/mL, which were administered undiluted via servocontrolled syringe pumps.
The vital signs monitored included heart rate (HR), respiratory rate (RR), and mean arterial pressure (MAP), determined by electronic averaging of the tail arterial waveform. Sedation was graded according to a 6-point scale (see Table 1 ) based on behavioral and reflex activity of rats observed under progressively deepening levels of propofol sedation in pilot studies. Arterial blood gas data were obtained from 0.5-mL heparinized samples of tail arterial blood. The lidoCaine levels at seizure threshold were determined from 1 mL of plasma analyzed by gas chromatography (1'4.
Real-time and spectral EEG analyses were obtained from platinum needle electrodes sutured into the scalp overlying the midline and 3 mm to the right and left of midline overlying the parietal cortices, with a ground electrode sutured into the dorsal midline of the back. The right and left cortical scalp electrodes were referred to the midline electrode, and symmetrical activity in both cortices was present throughout the experiment. A Tracer Nomad Model 3400 electrophysiologic monitoring system (Dynamic Engineering Corp., Madison, WI) was used, with a maximal gain of 1 X 106, lo-bit resolution, 10 ps sample/conversion time, analog-to-digital conversion by successive approximation, and l-3000 Hz bandpass with a 60-Hz notch filter; resting EEG amplitudes typically ranged from 1 to 5 pV, and seizure spikes ranged from 10 to 20 pV. Seizure activity was defined to commence with the onset of isolated EEG spike activity. Some or all of these associated phenomena occur with seizure onset: stereotypic brisk extensor movements of the body, often accompanied by synchronous whisker and tail movements; exophthalmic gaze with preserved corneal reflexes, urination, and occasional chewing movements. The rats achieved a stable level of sedation before the onset of seizure. Under such circumstances, there is no muscle artifact activity to obscure the appearance of seizure spikes, and, therefore, determination of seizure onset is unequivocal. The EEG seizure activity begins as isolated high-voltage spikes and polyspikes, which initially cluster into periods of continuous activity interrupted by periods of electrical quiescence, culminating in uninterrupted status epilepticus until the onset of cardiac arrest. Death occurs with the abrupt onset of bradycardia and hypotension, proceeding rapidly to asystole and apnea.
The data are reported as mean values + SEM. lnterval data were analyzed by using one-way analysis of variance (ANOVA) for between-group comparisons, and repeated-measure ANOVA for within-group comparisons. The ANOVA and repeated-measure ANOVA results were analyzed post hoc using Dunnett's t-test for comparisons with the control value, with significance levels set at P < 0.05. Noninterval data were analyzed by using the Kruskal-Wallis test. Spearman's rank-order correlation was used to test for an association between sedation and dose. Other interval data, including lidocaine levels and lidocaine doses, were analyzed for correlation with propofol dose using Pearson's product-moment correlation.
Results
The drug infusions demonstrated mild effects on circulation and respiration. Lidocaine invariably produced a significant slowing of HR before seizure onset in all groups tested. Although propofol produced a slight increase in HR compared with baseline for the two larger doses (Dose 2 rats' HR increased from 348 2 5 to 396 + 17 bpm, P < 0.05; Dose 3 rats' HR increased from 336 ? 11 to 372 + 10 bpm, P < 0.05), this was not enough to offset the subsequent HRslowing effects of lidocaine just before seizure onset ( Table 2) . None of the HR changes was associated with a significant change in MAP (Table 2) . At its largest dose (Dose 3), propofol increased RR from 73 + 6 to 91 t 8 breaths/min (P < 0.05), which was associated with a slight reduction in Pao, (82.6 -+ 5.8 mm Hg for Dose 3 rats compared with 100.4 + 7.4 mm Hg for control rats, P < 0.05) but caused no respiratory effects at smaller doses (Table 3) . ln control rats, lidocaine exerted a slight decrease of Pacoz, from 36.7 + 0.9 to 34.7 ? 0.7 mm Hg just before seizure onset, which was not seen in the rats receiving propofol (Table 4) . The arterial pH, however, did not change significantly in any of these groups. ANESTH ANALG 1998; 86:652-7 LEE ET AL. 655 PROPOFOL SUPPRESSES LIDOCAINE SEIZURES Propofol given according to the three previously described dosage schedules produced a dosedependent sedating effect. The highest level of sedation achieved was Grade 3, achieved after the largest propofol dose (Dose 3). Grade 3 sedation represents somnolence characterized by loss of righting reflex and auditory startle reflex but is subanesthetic because the tail pinch response is still intact. Kruskal-Wallis analysis demonstrated significant differences in sedation among the different groups (as defined in Table 1 ) at the P < 0.0001 level. Sedation was correlated with propofol dose at the P < 0.001 level, with a rank-order correlation of 0.9263 (Fig. 1) .
The control rats achieved seizure threshold levels of lidocaine within 13.2-20.3 min and cardiac arrest within 23.3-47.3 min. Continuous propofol sedation resulted in an increase in the seizure dose of lidocaine (Fig. 2) . Lidocaine-induced seizures were completely absent at Dose 3. The lidocaine levels at seizure threshold were increased in the propofol-treated rats (Fig. 3) . The lethal dose of lidocaine-89.4 -+ 10.5 mg/kg control versus 108.7 + 10.3 mg/kg (Dose l), 98.3 + 10.1 mg/kg (Dose 2), and 93.5 2 10.4 mg/kg (Dose 3)-did not differ significantly among groups, Both seizure doses of lidocaine and seizure blood levels of lidoCaine correlated significantly with the propofol dose at the P < 0.01 level, with Pearson's Y = 0.692 for seizure doses and 0.727 for seizure blood levels.
Discussion
There has been considerable concern in the literature as to whether propofol should be considered a proconvulsant drug because of isolated case reports of neuroexcitatory phenomena, such as opisthotonus and tonic-clonic motor activity, occurring in conjunction with propofol anesthesia (1,2,13-17). The actual incidence of such events is unknown, but it is presumably low and has not resulted in substantial restrictions in the clinical use of propofol in nonepileptic patients. The potential of propofol to induce seizures 0 1 2 3 Figure   1 . Distribution of sedation scores among the control and experimental groups. Sedation scores are defined in Table 1 . The highest sedation score (score = 3) was achieved by three rats in the propofol Dose 3 group. The correlation of the level of sedation with the propofol dose was significant at the P < 0.001 level, with a Spearman's rank order correlation of 0.9263. in epileptic patients is also unclear, with some isolated accounts suggesting that propofol is responsible for epileptiform activity in patients previously diagnosed with epilepsy (2,4,18). On the other hand, conflicting reports have cited propofol's ability to potentiate EEG seizure spike activity (3), suppress spike activity (19-21), or leave epileptogenic activity unchanged (22) in epileptic patients undergoing seizure focus mapping. In some situations, propofol seems to exert anticonvulsant effects and has been used successfully in the treatment of status epilepticus due to viral encephalitis (23) and drug overdose (24). Propofol decreases the seizure duration in electroconvulsive therapy (25-28) compared with thiopental or methohexital. One case report details the occurrence of seizure-like activity in a patient, presumably due to lidocaine toxicity, which was successfully treated with a bolus dose and infusion of propofol (29).
In a variety of animal models of epilepsy, including chemically induced seizures (pentylenetetrazol, strychnine, laudanosine) and electroshock-induced seizures in species including mice, rats, and rabbits, propofol inhibits or attenuates seizure activity (5-8,30,31 regard to local anesthetic toxicity, two animal investigations of bupivacaineand lidocaine-induced seizures, respectively, reported the inhibition of seizures with propofol infusions in rats (9,10), although both of these studies involved paralyzed, mechanically ventilated rats that were receiving other anesthetics in addition to the propofol (such as nitrous oxide and halothane), and the propofol doses were not selected based on the level of sedation achieved in the rats.
In the present study, propofol doses were selected based on the actual sedative effect achieved in the rats. The importance of investigating this particular dose range of propofol has to do with the frequently encountered clinical situation in which human patients are sedated, but not anesthetized, with propofol and are maintaining a natural airway and spontaneously breathing while undergoing surgery under regional or local anesthesia. The concern in this situation is the possibility of achieving borderline toxic systemic levels of local anesthetics during the administration of a regional or local anesthesia, and whether propofol sedation results in potentiation or inhibition of local anesthetic-induced seizure activity. In the present study, we investigated doses of propofol that achieved gradually deepening levels of sedation. Failure to inhibit a behavioral response to forceps tail pinch confirms that the doses were subanesthetic. The correlation between the magnitude of the sedating doses of propofol and the degree of increase in lidocaine doses and lidocaine plasma levels required to achieve seizure threshold confirms that propofol exerts an anticonvulsant effect within this dose range. Moreover, this effect is dose-dependent in a monotonic fashion, the culmination of which is complete seizure suppression at the largest sedating dose. The monitoring of circulatory and respiratory variables, including arterial blood gases, suggested that the effects of propofol or lidocaine on circulation and respiration were minimal and did not seem to introduce confounding effects on the seizure-induction model. Because of the frequent association of myoclonic activity with propofol doses in humans and other species, the possibility of a subcortical focus of neuroexcitatory activity must be considered. Lidocaineinduced seizures seem to originate from subcortical sites, specifically the amygdala and hippocampus (32). However, subcortical depth electrode monitoring of the hippocampus in epileptic patients did not reveal noticeable changes in electrical activity in this area of the brain in response to graded doses of propofol (22); perhaps the presence of epilepsy itself was a confounding factor. The mechanism of propofol-induced neuroexcitatory activity is unclear, although glycine antagonism has been suggested (33). On the other hand, lidocaine-induced seizures seem to be facilitated by brain monoaminergic systems (34,35), although this observation seems to critically depend on the methodology used (36), and competitive N-methyl-naspartate receptor antagonists may be capable of suppressing these seizures (37).
Propofol given in sedating doses to spontaneously breathing rats receiving no other anesthetics seems to inhibit lidocaine-induced seizures in a monotonic, dose-dependent fashion. Extrapolation to the clinical situation must be done cautiously, because species differences may play a role in the differential pro-and anticonvulsant activities of propofol. 
